Grey Wolf secures $50m for antigen modulation technology

Grey Wolf Therapeutics has successfully completed a $50 million expansion to its Series B financing, aimed at advancing its antigen modulation technology. The financing round, led by ICG’s Life Sciences team with contributions from existing investors including Pfizer Ventures, Canaan, Andera Partners, Oxford Science Enterprises, and Earlybird Venture Capital, brings the total Series B funding to $99 million.

The company plans to use this newly acquired capital to extend the ongoing Phase I/II clinical trial of its leading immuno-oncology candidate, GRWD5769, which targets solid tumors. This candidate, an oral ERAP1 inhibitor, has shown promising results by eliciting a strong immune response against cancer cells.

The additional funds will also support the expansion of Grey Wolf’s research and development efforts into new therapeutic areas. This includes exploring the potential of their antigen modulation technology for treating autoimmune diseases. The company’s second ERAP1 inhibitor, GRWD0715, currently in preclinical development, is slated to enter clinical trials by 2025.

Tracy Weightman, associate director of Life Sciences at ICG, has joined Grey Wolf’s board of directors, providing further strategic guidance as the company advances its clinical and preclinical programs.

Peter Joyce, CEO of Grey Wolf Therapeutics, expressed that the Series B expansion funding will enable the company to broaden its clinical trial for GRWD5769, including patients with a wider variety of tumor types and exploring new combination treatment strategies. Additionally, the capital will allow the company to further investigate the potential therapeutic applications of its antigen modulation technology.

Joyce highlighted the growing body of clinical research and genetic evidence supporting the potential of ERAP inhibition to become a groundbreaking approach for disease-modifying therapies in autoimmune diseases. With this in mind, Grey Wolf is intensifying its R&D efforts to evaluate the broader applications of their unique technology.